ADAMTS13 and thrombotic thrombocytopenic purpura: Untreated TTP has mortality rates up to 90% and immediate treatment with plasma exchange (PE) in order to remove circulating antibodies and replace with functional ADAMTS-13 and vWF, as well as additional treatment with caplacizumab and rituximab is crucial [4].